The device component of the first biosimilar in an on-body Injector

Tuesday, October 28, 2025 5:00 PM to 9:00 PM · 4 hr. (Africa/Abidjan)

Information

LTS Lohmann's Device Technologies team created a device for the first Biosimilar Marketed in an OBI. This is the Udenyca(TM) On-Body Developed by Coherus Biosciences and now owner by Accord/Intas.

In doing so, LTS worked diligently with the FDA and their Pharmaco partner to make improvements to the speed of delivery, needle deployment mechanism, adhesive patch geometry, and fill indicator.

This has enabled their biosimilar partner to:

a) better the patient experience without confusing those migrating from the reference biologic

b) improve the attractiveness of their product in a typically cost-driven landscape

c) Protect their molecule from price erosion and thus increase the attractiveness of all biosimilars' manufacturers to continue increasing affordable access to their medicine.

d) Increase market share from 18% to 41% within 1 year.

LTS-Lohmann Therapie-System AGLTS LOHMANN Therapie-Systeme AG is a trusted technology partner for the pharmaceutical industry! We develop and manufacture innovative drug delivery systems such as Transdermal Patches ( TTS ) and Oral Thin Films ( OTF ) as well as wearable drug delivery devices ( OBDS ). The experience of LTS is based on more than 20 marketed products and a diverse development pipeline. LTS maintains its leading postion by advancing emerging drug delivery technologies, including Microneedle Array Patches ( MAP ) for the transdermal delivery of small and large molecules, biological and vaccines.

The device component of the first biosimilar in an on-body Injector

Information

Log in

Log in